NVO

Novo Nordisk A/SA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$60.00

+39.8% vs current

Most likely

Base case

50%

Probability

Target price

$51.00

+18.8% vs current

B-

Bear case

25%

Probability

Target price

$35.50

-17.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Primary-source company releases now confirm the Q1 volume/guidance inflection and the two CHMP opinions, so the core evidence gap is closed. Peer framing now focuses on direct obesity and diabetes competition from Lilly plus obesity-development read-throughs from Amgen and Viking, but analyst revision data is unavailable in the packet, social context is absent, and the deterministic prior still points to weak near-term returns. This remains a cautious monitoring view rather than a clean bullish rerate.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-04-29catalystDenecimig keeps haemophilia A as a diversification laneMedium impact

NEJM published phase 3 FRONTIER2 results for denecimig (Mim8), reinforcing a longer-dated non-obesity diversification path for the pipeline [#PR-2026-04-29-DENECIMIG].

2026-05-06catalystQ1 2026 GLP-1 volume and guidance inflectionMedium impact

Q1 adjusted operating profit reached DKK 32.9bn, and Novo said Wegovy pill had more than 1 million people since launch and over 2 million cumulative prescriptions; the quarter also reflected the March FDA approval and April U.S. launch of Wegovy HD, plus pre-launch pipeline fill [#IR-2026-05-06-Q1].

2026-09-30eventEU CHMP backs Wegovy 7.2 mg launch pathMedium impact

CHMP also recommended Wegovy 7.2 mg in a single-dose pen, and Novo expects a Q3 2026 EU launch for the higher-dose injection [#IR-2026-05-22-WEGOVY-7.2MG].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology